AZN 250110 67.00C (AZN250110C67000) Stock Options, News & Quotes

US OptionsDetailed Quotes

AZN250110C67000

Watchlist

0.01
0.000.00%

15min DelayTrading Jan 10 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

AstraZeneca Put Volume Heavy and Directionally Bearish
TipRanks4minutes ago
Monopar Therapeutics Gains 'Buy' Rating Amid Promising Licensing Deal With AstraZeneca and Strong Growth Prospects
TipRanks07:16 ET · Ratings
Leerink Partners Maintains AstraZeneca(AZN.US) With Buy Rating, Maintains Target Price $87
Moomoo News22:33 ET · Ratings
AstraZeneca's Strategic Positioning and Datroway Approval Drive Buy Rating Amidst Evolving Breast Cancer Treatment Landscape
TipRanks22:25 ET · Ratings
Takeda-backed Ascentage Pharma Sets Terms for $170M IPO
Seeking Alpha18:30 ET
Analysts' Opinions Are Mixed on These Healthcare Stocks: AstraZeneca (GB:AZN), CSL (OtherCMXHF) and UCB SA (GB:0NZT)
TipRanksJan 21 04:02 ET · Ratings

Comments

Stock_Drift

Jan 18 08:51

$GlaxoSmithKline (GSK.US)$ $Amgen (AMGN.US)$ $AstraZeneca (AZN.US)$

Ozempic, Xtandi among next 15 drugs selected for U.S. price talks

Stock_Drift

Jan 17 17:48

$AstraZeneca (AZN.US)$

Phil Dunn

Jan 12 00:08

Weekly Trading Report (2nd Week Jan)

A Quick Review of my Trading Activities in this week ( 6 - 10 Jan 2025 ).
Market Overview
- US 10 Year Treasury yield is rising continuously because of high inflation expectation ( fear of high US tariffs ) and strong US economy ( low unemployment rate and strong consumers spending ).
- US 10 Year Treasury yield is approaching 5% ( 5% was highest record since Fed hiked rate last 2 years ) and put large downward pressure to stock markets broadly. ( Yield curren...

December CPI comes in as expected, is that enough?

Meltyy

Dec 17, 2024 01:56

📌 1 PDUFA this weekand 6 more upcoming this month! 🚀

🔔 This Week’s PDUFA:
$Ionis Pharmaceuticals (IONS.US)$ : 🤔
⇨ IONIS-APOCIII-LRx (Olezarsen)
‣ FCS (Familial chylomicronemia syndrome)
‣ PDUFA: 12/19/24 (NDA)
🗓️ Last Week’s PDUFA Decisions:
$Checkpoint Therapeutics (CKPT.US)$ : Approved 12/13/24 ✅
⇨ UNLOXCYT (cosibelimab-ipdl)
‣ metastatic or locally advanced cSCC (cutaneous squamous cell carcinoma)
‣ PDUFA: 12/28/24 (resubmitted BLA)
$Neurocrine Biosciences (NBIX.US)$ : Approved 12/13/24 ✅
⇨ CRENESSITY™ (crin...

10xStockPicks

Dec 15, 2024 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...